ULCERATIVE COLITIS

A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study for induction and maintenance therapy in moderate-to-severe ulcerative colitis.

You may qualify if:

• Male and female patients aged 18 - 80 years.
• Ulcerative Colitis diagnosed more than 3 months ago.
• Previous treatment failure to approved or experimental immunomodulators (azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate, or tofacitinib) or biologics or are corticosteroid dependent.